All ETDs from UAB

Advisory Committee Chair

Xiaoguang Margaret Liu

Advisory Committee Members

Gangjian Qin

Lufang Zhou

Runhua Liu

Wuqiang Zhu

Document Type

Dissertation

Date of Award

2018

Degree Name by School

Doctor of Philosophy (PhD) School of Engineering

Abstract

Cancer is one of the leading causes of mortality globally, and multiple anti-cancer therapies have been developed and applied over last few decades. Antibody-based cancer therapies have been on one of the most exciting and promising therapeutic strategies. Monoclonal antibodies (mAbs) can control the progression of cancers via targeted binding to the specific antigen of tumors to trigger an immune response, target and block the signaling pathway involved in cancer progression, or deliver cytotoxic agents into tumors. Two chimeric/humanized monoclonal antibodies (anti-HER2 mAb and anti-CD 20 mAb) with higher efficacy were successfully expressed in engineered Chinese Hamster Ovary Cells (CHO). A robust platform was established and optimized for large-scale, high quality mAbs manufacturing. The in vitro studies, e.g. binding affinity of antibody to cancer cells were performed to evaluate the bio-function of the antibody produced in stirred-tank bioreactor. In addition, advanced Omics technologies, e.g. proteomics, were used to identify novel surface markers, enrich the knowledge of cellular metabolism and physiology, and guide cell engineering and bioprocess optimization. The antibody production platform and the deep understating of antibody expression regulation can also benefit the development of other promising antibody-based therapies (e.g. antibody-drug conjugate and antibody-based cell therapy) in the future.

Included in

Engineering Commons

Share

COinS